The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.

Find out what it means to be in remission when you have follicular lymphoma, and learn why checkups and maintenance therapy are important parts of your care plan.

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low tumor burden follicular lymphoma can substantially delay the need for ...

Rituximab has become the mainstay of systemic therapy for patients with follicular lymphoma and is associated with an improved outcome at both diagnosis and relapse, either as induction or ...

ATLANTA -- Patients with newly diagnosed low-burden follicular lymphoma (FL) in remission avoided chemotherapy significantly longer if they received maintenance rituximab (Rituxan) instead of ...

Rituximab, a monoclonal anti-CD20 antibody, in combination with chemotherapy improves overall survival compared to chemotherapy alone when used for induction therapy for patients with newly diagnosed ...

Rituximab maintenance following induction immunochemotherapy conferred durable PFS compared with observation among patients with follicular lymphoma, according to long-term results of the ...

The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS ...